BALAXI PHARMACEUTICALS LIMITED — PPTs, 14-11-2025: Investor Presentation

Balaxi Pharma saw a challenging Q2 FY26 with revenue down 27% YoY to ₹56.17 Cr, impacted by softer demand, working capital pressure, and shipping delays. Profit after tax fell 95.4% to ₹0.21 Cr, partly due to increased operational costs from a strategic shift to institutional markets. However, gross profit margin improved to 48.3%.

Key development: The company completed its first manufacturing facility in Hyderabad, aiming for backward integration and better margins. Initial product batches are now undergoing stability studies, with GMP audit preparations underway. Balaxi also added 6 new product registrations, taking its total to 935.

Management acknowledges near-term hurdles but expects the new facility and regulatory progress to drive long-term operational integration, margin growth, and market expansion into new Latin American and other frontier markets.